Mesenchymal stem cells as anti-inflammatories: Implications for treatment of Duchenne muscular dystrophy

被引：114

作者：

Ichim, Thomas E. ^{[1
]}

Alexandrescu, Doru T.

Solano, Fabio ^{[2
]}

Lara, Fabian ^{[2
]}

Campion, Rosalia De Necochea ^{[3
]}

Paris, Eugenia ^{[4
]}

Woods, Erik J.

Murphy, Michael P. ^{[5
]}

Dasanu, Constantin A. ^{[6
]}

Patel, Amit N. ^{[7
]}

Marleau, Annette M. ^{[8
]}

Leal, Alejandro ^{[9
,10
]}

Riordan, Neil H. ^{[1
]}

机构：

[1] Medistem Inc, San Diego, CA 92122 USA

[2] Inst Cellular Med, Panama City, Panama

[3] Univ Calif San Diego, San Diego, CA 92103 USA

[4] Hosp CIMA, San Jose, Costa Rica

[5] Indiana Univ, Sch Med, Div Med, Bloomington, IN 47405 USA

[6] St Francis Hosp & Med Ctr, Dept Hematol & Med Oncol, Hartford, CT USA

[7] Univ Utah, Dept Cardiothorac Surg, Salt Lake City, UT USA

[8] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE USA

[9] Univ Costa Rica, Sch Biol, San Jose, Costa Rica

[10] Univ Costa Rica, Neurosci Res Program, San Jose, Costa Rica

来源：

CELLULAR IMMUNOLOGY | 2010年 / 260卷 / 02期

关键词：

Duchenne muscular dystrophy; Endometrial regenerative cells; Mesenchymal stem cells; Regenerative medicine; Cord blood stem cells; T regulatory cells; Inflammation; Immune modulation; Stem cell therapy; VERSUS-HOST-DISEASE; TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEMATOLOGIC MALIGNANCY PATIENTS; NORMAL MYOGENIC CELLS; UMBILICAL-CORD BLOOD; MARROW STROMAL CELLS; CC CLASS CHEMOKINES; BONE-MARROW;

D O I：

10.1016/j.cellimm.2009.10.006

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Duchenne muscular dystrophy (DMD) is a lethal X-linked musculodegenerative condition consisting of an underlying genetic defect whose manifestation is augmented by inflammatory mechanisms. Previous treatment approaches using gene replacement, exon-skipping or allogeneic cell therapy have been relatively unsuccessful. The only intervention to mediate improvement in survival, albeit minor, is glucocorticoid treatment. Given this modality appears to function via suppression of underlying inflammation; we focus this review on the inflammatory response as a target for mesenchymal stem cell (MSC) therapy. In contrast to other cell based therapies attempted in DMD, MSC have the advantages of (a) ability to fuse with and genetically complement dystrophic muscle; (b) possess anti-inflammatory activities; and (c) produce trophic factors that may augment activity of endogenous repair cells. We conclude by describing one practical scenario of stem cell therapy for DMD. (C) 2009 Elsevier Inc. All rights reserved.

引用

页码：75 / 82

页数：8

共 152 条

[31] Mobilization of endothelial progenitor cells into the circulation in burned patients [J].